on INVENTIVA (EPA:IVA)
Inventiva presents an abstract at the Liver Meeting™ 2024
Inventiva announces that its Phase II clinical trial, LEGEND, combining lanifibranor and empagliflozin, has been selected as a late breaker abstract for the Liver Meeting™ 2024, organized by the American Association for the Study of Liver Diseases. The event will be held in San Diego from November 15 to 19, 2024.
The LEGEND study is evaluating the combination of lanifibranor with empagliflozin in patients with metabolic steatohepatitis (MASH) and type 2 diabetes. It will be presented as a poster on November 18 by a team of experts, including Michelle Lai and Onno Holleboom.
Lanifibranor, developed by Inventiva, is known for its anti-fibrotic and anti-inflammatory effects in treating NASH. The company, listed on Euronext Paris and Nasdaq, continues to develop and test this treatment globally.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INVENTIVA news